Loading...

Ajanta Pharma Limited Buyback (Ajanta Pharma Buyback 2023) Detail

Incorporated in 1979, Ajanta Pharma Limited is a specialty pharmaceutical company offering quality medicines across more than 30 countries in the world.

The company understands its customers' requirements and develops products to suit their needs with the help of cutting-edge technology to present innovative solutions.

The business of Ajanta Pharma includes Branded Generics in India and Emerging Markets in Asia and Africa; Generics in the USA; and Institution Sales in Africa. With diversified revenue streams, their business model is highly scalable and sustainable.

Ajanta Pharma operates through its 7 state-of-the-art manufacturing facilities situated in India. 6 of the company's facilities manufacture finished formulations and 1 manufactures Active Pharmaceutical Ingredients (APIs) primarily for captive consumption. The high-quality medicines of the company are trusted by healthcare professionals and patients in over 30 countries.

Ajanta Pharma Buyback 2023 Detail

Issue Period
Security NameAjanta Pharma Limited
Issue TypeTender Offer
Issue Size (Shares)2,210,500.00
Issue Size (Amount)₹315.00 Crores
Buyback Price₹1425 per share
Face Value₹2 per share
Listing AtBSE, NSE

Ajanta Pharma Buyback 2023 Issue Timetable

Last Date to buy sharesMar 23, 2023
Record DateMar 24, 2023
Offer Opens On
Last Date for receipt of Tender Forms
Offer Closes On
Finalisation of Buyback Acceptance
Last Date for settlment of bids
Last Date for Extinguishment of Shares

Buyback Ratio

[.]

Company Financials

Ajanta Pharma Limited Financial Information (Restated Consolidated)
Period EndedTotal AssetsTotal RevenueProfit After Tax
31-Mar-213,778.722,915.67653.87
31-Mar-224,055.583,456.67712.68
Amount in ₹ Crore

Necessity of the Issue

The buyback is being undertaken for the following reasons:

  1. The buyback will help the company to return surplus cash to its equity shareholders broadly in proportion to their shareholding, thereby enhancing the overall return to shareholders.
  2. The buyback consists of a reservation for the small shareholder. The company believes that this reservation for small shareholders would benefit a large number of public shareholders who would get classified as "small shareholders".
  3. The buyback may help in improving return on equity, reduction in the equity base, thereby leading to a long-term increase in shareholders' value.
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.
  5. The buyback may lead to a reduction in outstanding Equity Shares, an improvement in earnings per equity share, and an enhanced return on equity.

Ajanta Pharma Buyback 2023 Documents

Ajanta Pharma Buyback 2023 Rating

4
3.5
Rating:Rated 3.5 stars
Vote Here ...

Ajanta Pharma Buyback 2023 Reviews

Sorry, we couldn't find any reviews, please check back later.

Company Contact Information

Ajanta Pharma Limited
Ajanta House, Charkop,
Kandivali West,
Mumbai 400 067

Phone: +91 22 6606 1000
Email: legal.info@ajantapharma.com
Website: http://www.ajantapharma.com/

Ajanta Pharma Buyback 2023 Registrar

  1. Link Intime India Private Ltd
       Link Intime India Private Ltd
       C 101, 247 Park, L.B.S.Marg,
       Vikhroli (West), Mumbai - 400083

    Phone: +91-22-4918 6270
    Email: ajantapharma2023.buyback@linkintime.co.in
    Website: https://linkintime.co.in/

Ajanta Pharma Buyback 2023 Manager

Find Ajanta Pharma Buyback 2023 Latest Update

Ajanta Pharma Buyback 2023 FAQs

The Ajanta Pharma Buyback 2023 open and close dates are not available as of now.

Last date to be eligible to participate in buyback is Mar 23, 2023.

The Ajanta Pharma Buyback 2023 is a Tender Offer.

Sorry the Ajanta Pharma Buyback 2023 timelines are not available at this time.

The Ajanta Pharma Buyback 2023 is being offered at Rs ₹1425 per share per equity share.

[.]

The record date for the Ajanta Pharma Buyback 2023 is Mar 24, 2023.

The issue size of Ajanta Pharma Buyback 2023 is of 2,210,500.00 equity shares at ₹1425 per share aggregating upto ₹315.00 Crores.

The buyback is being undertaken for the following reasons:

  1. The buyback will help the company to return surplus cash to its equity shareholders broadly in proportion to their shareholding, thereby enhancing the overall return to shareholders.
  2. The buyback consists of a reservation for the small shareholder. The company believes that this reservation for small shareholders would benefit a large number of public shareholders who would get classified as "small shareholders".
  3. The buyback may help in improving return on equity, reduction in the equity base, thereby leading to a long-term increase in shareholders' value.
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.
  5. The buyback may lead to a reduction in outstanding Equity Shares, an improvement in earnings per equity share, and an enhanced return on equity.

All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.

The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.

The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.

The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.

The Ajanta Pharma Buyback 2023 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.


2 Comments

2. Helloji   I Like It. |Report Abuse|  Link|Mar 14, 2023 11:34:34 AMReply
There is no guarantee one share strategy will work. You are assuming number of small shareholders won't change. Suppose that 1 crore investors buy 1 share each between now and record date. Then there is no way that all of them will be able to sell 1 share each.
2.1. bhagyesh   I Like It. |Report Abuse|  Link|Mar 18, 2023 7:55:25 PM
i have working since 2 years one share is buyback is working with me
1. Kousik Chakravarti   I Like It. 1|Report Abuse|  Link|Mar 10, 2023 9:08:18 PMReply
1 share strategy will surely work here like vrl,sportking,symphony and hgs.The calculation regarding 1 share strategy for small shareholders is explained in comment no 1.6 of hinduja global solutions buyback.